Evidence map›Paper›PMID 41291692›Full record

ArticleJournal of nanobiotechnology2025

Ion-interference amplifier nano-system enhances radiotherapy via mitochondrial dysfunction and efferocytosis Inhibition.

Shuting Zheng, Yinfei Zheng, Honglei Hu, Minyi Liu, Chenxi He, Zede Wu, Meirong Hou, Guoqiang Liu, Yikai Xu, Chenggong Yan and 1 more

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shuting Zheng *Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Yinfei Zheng *Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Honglei Hu *Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Minyi LiuCancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
Chenxi HeDepartment of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Zede WuDepartment of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Meirong HouDepartment of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Guoqiang LiuInstitute of Electrical Engineering, Chinese Academy of Sciences, Beijing, 100190, China.
Yikai XuDepartment of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. yikaixu917@gmail.com.
Chenggong YanDepartment of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. ycgycg007@gmail.com.
Bingxia ZhaoCancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China. bingxiaz@gmail.com.

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2021A1515012542Basic and Applied Basic Research Foundation of Guangdong Province 2025A1515011139Guangdong Provincial Pearl River Talents Program 2017GC010282National Natural Science Foundation of China 51937010National Natural Science Foundation of China 82302140
6 · The paper itself

Abstract

backgroundThe efficacy of radiotherapy (RT) is often compromised by tumor radioresistance and an immunosuppressive microenvironment. Two key limitations are the clearance of apoptotic cells (efferocytosis), which can promote an immunosuppressive phenotype, and the acidic tumor microenvironment (TME) that further restrains antitumor immunity. An ideal radiosensitizer should not only enhance radiation-induced cell death but also address these immunological barriers to unlock robust systemic antitumor immunity.

methodsWe constructed a multifunctional nano-system based on mesoporous organosilicon (HMON) as a template. Leveraging the tunability of the -Si-O-Si- framework, we incorporated manganese (Mn) and calcium (Ca) elements to form a unique -Si-O-M- hybrid structure (M = Mn or Ca). This composite was subsequently loaded with Omeprazole sodium (PPI) and efferocytosis inhibitor, and the surface was modified with hyaluronic acid (HA) for active targeting. In vitro, the radiosensitizing mechanism was investigated in 4T1 cells via western blot, immunofluorescence and flow cytometry. In vivo efficacy was evaluated in 4T1 tumor-bearing BALB/c mice following combined nano-system and RT treatment.

resultsThe resulting nano-system exhibited a high T1 relaxivity (r1 = 8.95 mM⁻¹s⁻¹). In vitro and in vivo studies demonstrated that it significantly enhanced radiation-induced oxidative stress and mitochondrial dysfunction. The combination therapy achieved a remarkable ~ 96% tumor growth inhibition in 4T1 tumor-bearing mice. Crucially, it potentiated immunogenic cell death and activated the cGAS-STING pathway, evidenced by a > 3-fold increase in mature dendritic cells (DCs) and a > 4-fold enhancement in tumor-infiltrating cytotoxic T lymphocytes.

conclusionThis study presents a novel "ion-interference amplifier" strategy that concurrently enhances radiosensitization and immune response, offering a powerful model for synergistic radio-immunotherapy. Meanwhile, the integration of MRI-based tracking further underscores its potential for clinical translation.

Indexed as

EfferocytosisMitochondriaNeoplasms, ExperimentalRadiation-Sensitizing AgentsRadioimmunotherapyAnimalsCalciumCell LineFemaleHyaluronic AcidManganeseMiceMice, Inbred BALB CNanoparticlesOmeprazoleOrganosilicon CompoundsCalciumHyaluronic AcidManganeseOmeprazoleOrganosilicon CompoundsRadiation-Sensitizing AgentsReactive Oxygen SpeciesEfferocytosis inhibitionMolecular imagingpH regulationRadiosensitizationTumor microenvironment

Identifiers

PMID41291692
PMCPMC12649073

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.